| 000 | 01542 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518092754.0 | ||
| 264 | 0 | _c20210412 | |
| 008 | 202104s 0 0 eng d | ||
| 022 | _a1872-8332 | ||
| 024 | 7 |
_a10.1016/j.lungcan.2020.03.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSherman, Shira | |
| 245 | 0 | 0 |
_aEfficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). _h[electronic resource] |
| 260 |
_bLung cancer (Amsterdam, Netherlands) _c05 2020 |
||
| 300 |
_a40-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aCarcinoma, Large Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmune Checkpoint Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aSmall Cell Lung Carcinoma _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aRotem, Ofer | |
| 700 | 1 | _aShochat, Tzippy | |
| 700 | 1 | _aZer, Alona | |
| 700 | 1 | _aMoore, Assaf | |
| 700 | 1 | _aDudnik, Elizabeth | |
| 773 | 0 |
_tLung cancer (Amsterdam, Netherlands) _gvol. 143 _gp. 40-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lungcan.2020.03.008 _zAvailable from publisher's website |
| 999 |
_c30772210 _d30772210 |
||